by
Lisa Chamoff, Contributing Reporter | October 29, 2018
From the October 2018 issue of HealthCare Business News magazine
Users have full access to the system through Android or iOS devices and the company introduced a structured way of handling workflows. If a user is logged on in a certain role, they will only see the tasks relevant to that role. The company has been updating RayCare to add functionality, including billing.
In June, the company released a new version of its RayStation treatment planning system that includes full planning capabilities for the TomoTherapy and Radixact systems from Accuray, and support for Accuray’s TomoDirect and TomoHelical delivery modes.
Later this year, RaySearch Laboratories plans to release an auto-contouring product that applies deep learning, with a database of “well-contoured” patients that will allow the process to be completely automated.
Varian
Varian recently released version 2.0 of its Halcyon radiotherapy system, which debuted at last year’s ESTRO meeting in Vienna.
The new version adds additional imaging modalities – kV cone beam CT and iterative cone beam CT, which Tracey Fisher, director of marketing for the Americas oncology division at Varian, said brings a “diagnostic-like” quality to the images.
“What is unique about Halcyon is the speed,” Fisher said. “You can get kV volumetric images in as few as 17 seconds. It’s better soft-tissue imaging and target delineation. The more you can see, the better is the potential treatment.”
The Halcyon is field upgradable, and since the launch Varian has taken 98 orders for the system worldwide.
The new version of Varian’s Eclipse treatment planning system, Eclipse 15.5, enables many of the features of the Halcyon 2.0 and a feature that allows clinicians to more easily adapt a treatment plan from one machine to another. Additionally, Eclipse 15.5 features Multicriteria Optimization (MCO), which allows clinicians to explore what happens when different clinical criteria are varied, such as the degree to which particular organs are spared versus coverage of the targeted tumor.
